MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company developing AI-powered voice analytics for real-time drug and alcohol impairment detection, is moving toward commercial deployment of its platform, with an initial focus on South America's mining sector. The company recently appointed Chilean drug policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a strategic push into industrial safety applications.
MindBio's technology analyzes voice patterns to detect intoxication or impairment without requiring biological testing, such as blood or saliva samples. Management positions the platform as a scalable tool for workplace safety in mining and other high-risk industries. Chile's mining sector, which employs more than 200,000 workers, represents an early target market. The company plans to begin deploying the platform in industrial environments starting in 2026.
The appointment of Leyton, a specialist in drug policy and harm reduction, is expected to facilitate MindBio's entry into the Chilean market. Leyton's expertise includes working with government agencies and industry stakeholders on substance use policies. His role will involve building partnerships with mining companies and regulatory bodies to integrate the voice-based impairment detection system into existing safety protocols.
MindBio also recently closed an upsized non-brokered private placement of up to $1.5 million to support commercialization activities. The capital is intended to fund further development of the AI platform, expand the sales team, and cover operational costs related to market entry.
The voice-based impairment detection technology addresses a growing need for non-invasive, rapid screening methods in industries where safety is critical. Traditional drug and alcohol testing methods, such as urine or breathalyzer tests, can be time-consuming and require specialized equipment. MindBio's approach uses machine learning algorithms to analyze acoustic features of speech that are altered under the influence of substances. The company claims the system can provide results in seconds, enabling real-time screening at entry points or during shifts.
If successful, the deployment in Chile's mining sector could serve as a proof of concept for other industrial applications globally. The mining industry, known for its hazardous working conditions, has a strong focus on safety compliance. Impairment detection is a key component of many safety programs, and automated voice-based screening could reduce risks associated with human error and subjective assessments.
For more information on MindBio Therapeutics and its latest developments, visit the company's newsroom at https://ibn.fm/MBQIF.
